Source ID: C21
Original URL: https://clinicaltrials.gov/study/NCT04622319
Source date (attachment preserved): 2020-11-09
Data date (attachment preserved): 2026-05-15
Checked at: 2026-10-07T18:42:25+08:00
Timezone: Asia/Taipei
Retrieval mode: stored_excerpt_review
Read level: 已存 ClinicalTrials.gov 官方公開 API 字段選錄；原始完整 HTTP JSON 未保存；本輪未網路重取
Access result: 已實讀原先保存的登錄日期、設計及必要排除字段；沒有用作者 clinical_records 結論替代
Original raw artifact SHA256: null

LOCATORS (actual reading positions):
research/clinical.json#/registry_records[source_id=C21]
原 API eligibilityCriteria 排除條件；本地 prior_adc_or_specific_exclusions[1]
本地 official_title；primary_outcomes[0]；status.lastUpdatePostDateStruct
Stored official API field extract: research/clinical.json#/registry_records[source_id=C21]
Official API used in original research: https://clinicaltrials.gov/api/v2/studies/NCT04622319
Original network read time: null
Original network read date (saved access_date): 2026-10-07

MINIMUM VERBATIM EXCERPT (only this block is source prose):
Prior treatment with T-DXd, T-DM1 or other anti-HER2 antibody-drug conjugate (ADC)

EXTRACTED FACTUAL FIELDS (not a reconstructed quotation):
[
  {
    "locator": "research/clinical.json#/registry_records[source_id=C21]/status.lastUpdatePostDateStruct",
    "date": "2026-05-15"
  },
  {
    "locator": "research/clinical.json#/registry_records[source_id=C21]/prior_adc_or_specific_exclusions[1]",
    "excluded_prior_treatment": [
      "T-DXd",
      "T-DM1",
      "other anti-HER2 ADC"
    ]
  },
  {
    "locator": "research/clinical.json#/registry_records[source_id=C21]/official_title",
    "comparison": [
      "T-DXd",
      "T-DM1"
    ],
    "population": "新輔助治療後高風險 HER2+ 乳癌殘餘侵襲病灶",
    "endpoint": "iDFS"
  }
]

SCOPE / PRECISE GAP (reviewer description, not source prose):
限原保存字段和該次登錄版本；不是結果論文、不是本輪刷新登錄。

Web refs: